21.97

1.44% -0.32

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $21.97, with a volume of 210.92K. It is down -1.44% in the last 24 hours and down -4.69% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Previous Close:

$22.29

Open:

$22.33

24h Volume:

210.92K

Relative Volume:

0.61

Market Cap:

$906.95M

Revenue:

Net Income/Loss:

$-136.98M

P/E Ratio:

-5.4652

EPS:

-4.02

Net Cash Flow:

$-126.63M

1W Performance:

-0.18%

1M Performance:

-4.69%

6M Performance:

-3.68%

1Y Performance:

-20.34%

1-Day Range:

$21.81

$22.81

1-Week Range:

$21.81

$22.81

52-Week Range:

$15.47

$29.71

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1131)

Industry

Biotechnology (633)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	21.97	920.16M	0	-136.98M	-126.63M	-4.02
VRTX Vertex Pharmaceuticals Inc	462.90	117.47B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	784.97	82.37B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.59	52.94B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	844.92	52.33B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.88	37.84B	447.02M	-1.18B	-906.14M	-6.1812

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

Dec 25, 2025

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha

Dec 25, 2025

(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Dec 25, 2025

Dec 24, 2025

ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat

Dec 24, 2025

Dec 22, 2025

ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Nigeria

Dec 22, 2025

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks

Dec 22, 2025

Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada

Dec 22, 2025

Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com

Dec 22, 2025

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks

Dec 22, 2025

ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com

Dec 22, 2025

ArriVent BioPharma Initiates Pivotal Phase 3 ALPACCA Study of Firmonertinib for First-Line Treatment of EGFR PACC Mutant NSCLC - Quiver Quantitative

Dec 22, 2025

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - marketscreener.com

Dec 22, 2025

New lung cancer trial tests a daily chemo-free pill for rare mutation - Stock Titan

Dec 22, 2025

Dec 20, 2025

Investment Recap: Will ArriVent BioPharma Inc. stock benefit from AI adoptionLong Setup & Daily Profit Maximizing Tips - Улправда

Dec 20, 2025

Will ArriVent BioPharma Inc. stock benefit from AI adoptionQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - Улправда

Dec 20, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 20, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 20, 2025

Dec 19, 2025

Will ArriVent BioPharma Inc. stock pay special dividendsTrade Volume Summary & Low Drawdown Investment Strategies - ulpravda.ru

Dec 19, 2025

Will ArriVent BioPharma Inc. stock remain a Wall Street favorite2025 Technical Overview & Real-Time Buy Zone Alerts - Улправда

Dec 19, 2025

Why ArriVent BioPharma Inc. stock is recommended by analystsMarket Trend Summary & Weekly Breakout Watchlists - Улправда

Dec 19, 2025

Dec 18, 2025

ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%Here's What Happened - MarketBeat

Dec 18, 2025

Will ArriVent BioPharma Inc. stock deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - Улправда

Dec 18, 2025

Dec 16, 2025

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha

Dec 16, 2025

Squarepoint Ops LLC Grows Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Dec 16, 2025

Dec 15, 2025

ArriVent BioPharma Earnings Notes - Trefis

Dec 15, 2025

Dec 14, 2025

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN

Dec 14, 2025

Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Dec 14, 2025

Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Dec 14, 2025

Dec 12, 2025

BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World

Dec 12, 2025

Dec 11, 2025